Supplemental Information
Figure S1. Distribution of 89 gastroenterologists/hepatologists (3,043 patients)
interviewed about HCV care in Taiwan a. Among 745,109 HCV patients, 330,819 (44.4%)
were from Southern Taiwan, 243,650 (32.7%) were from Northern Taiwan, 140,184 (18.8%) were from
Central Taiwan and 30,456 (4.1%) were from Eastern Taiwan.
Table S1. Gap between clinical efficacy and community effectiveness of HCV
Treatment in Taiwan a. Yu ML, Hepatology 2008; 47: 1884-1893. b. Yu ML, Gut 2007; 56:
553-559. c. Yang JF, Kaohsiung J Med Sci. 2011; 27: 258-263.
Table S2. Summaries of the gap between clinical efficacy and community
effectiveness. a. Yu ML, Hepatology 2008; 47: 1884-1893.
1
b.
Yu ML, Gut 2007; 56: 553-559.
Figure S1. Distribution of 89 gastroenterologists/hepatologists (3,043 patients)
interviewed about HCV care in Taiwan
a.
Among 745,109 HCV patients, 330,819 (44.4%) were from Southern Taiwan, 243,650 (32.7%) were from Northern Taiwan,
140,184 (18.8%) were from Central Taiwan and 30,456 (4.1%) were from Eastern Taiwan.
2
Table S1. Gap between clinical efficacy and community effectiveness of HCV Treatment in Taiwan
Correct
Clinical efficacy
Community
Access
Recommendation/Acceptance (B)
Diagnosis
(A)
Awareness (E)
(D)
Based
70-75% (type 1a/1b)a
effectiveness
(C)
54.8% (community-based)
(community
(A*B*C*D*E)
(community
c
/References
85-90% (type 2a/2b)b
50.0% (clinic-based)
Estimated
Weighted average:
Weighted average and adjusted for the
(anti-HCV
75%*(1/2)+85%*(1/2)
frequency of visits:
population)
=80%
54.5%*2/(54.5%*2+45.5%*1) =70.6%
80%
70.6%
-based)
-based)
39.6%
100%
36.2%
8.1%
39.6%
100%
48.7%
10.9%
Estimated
(HCV-viremic
population)
a.
Yu ML, Hepatology 2008; 47: 1884-1893. b. Yu ML, Gut 2007; 56: 553-559. c. Yang JF, Kaohsiung J Med Sci. 2011; 27: 258-263.
3
Table S2. Summaries of the gap between clinical efficacy and community effectiveness
Community
Clinical efficacy
Recommendation/
Access
Correct
Awareness
effectiveness
(A)
Acceptance (B)
(C)
diagnosis (D)
References
(E)
(A*B*C*D*E)
Holmberg SD,
U.S.
55.5%-77.3%
22%-30%
62.5%-75%
100%
50%
3.8-8.7%
NEJM, 2013
Denniston MM,
33.3%
U.S.
50.4%
100%
49.4%
4.1%-6.9%
Hepatology, 2012
50% (type 1)
83% (type 2/3)
Parkes J, BMC Public
5.6%
U.K.
2.8%-4.6%
Health, 2006
42% (type 1)
Niederau, C, WJG,
11-41%
Germany
100%
20%
1.1-4.1%
59% (type 2/3)
2012
75% (type1) a
70.6%
Taiwan
100%¶
39.6%
85% (type2/3) b
a.
Yu ML, Hepatology 2008; 47: 1884-1893.
b.
Yu ML, Gut 2007; 56: 553-559.
4
48.7%
10.9%
Current study